Form 483

Avalon Packaging, Inc. Form 483, 2020-12-21

FDA issued a Form 483 to Avalon Packaging, Inc. on 2020-12-21 with 6 public-safe observations.

483· Form 483 issuedFoods & Cosmetics6 observations

Avalon Packaging, Inc. · Orem, United States · Issued December 21, 2020

Overview

  • 6 public-safe observations are available for this inspection.
  • 6 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

21 Dec 2020
21 CFR 111.205(b)(1)

Master manufacturing record - specifications; quality

Cited by Jennifer A Robinson

21 Dec 2020
21 CFR 111.255(b)

Batch record - complete

Cited by Jennifer A Robinson

21 Dec 2020
21 CFR 111.65

Quality control - quality, dietary supplement

Cited by Jennifer A Robinson

21 Dec 2020
21 CFR 111.70(b)(2)

Specifications-component purity, strength, composition

Cited by Jennifer A Robinson

21 Dec 2020
21 CFR 111.70(c)(1)

In-process identity, purity, strength, composition

Cited by Jennifer A Robinson

Inspected site

APAvalon Packaging, Inc.Orem, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 111.205(b)(1)Cited across public-safe Form 483 observations1x
21 CFR 111.255(b)Cited across public-safe Form 483 observations1x
21 CFR 111.65Cited across public-safe Form 483 observations1x
21 CFR 111.70(b)(2)Cited across public-safe Form 483 observations1x
21 CFR 111.70(c)(1)Cited across public-safe Form 483 observations1x
21 CFR 111.70(e)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 6 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere